{"entity":{"id":"il33","kind":"target","name":"IL33","aka":["interleukin 33","Interleukin-33","DVS27","DKFZp586H0523","NF-HEV","IL1F11","C9orf26"],"tldr":"IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signalling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:16028","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16028"},{"label":"UniProt O95760","url":"https://www.uniprot.org/uniprotkb/O95760/entry"},{"label":"NCBI Gene 90865","url":"https://www.ncbi.nlm.nih.gov/gene/90865"},{"label":"Ensembl ENSG00000137033","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137033"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: High Grade Glioma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"IL33","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:16028","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16028","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O95760","url":"https://www.uniprot.org/uniprotkb/O95760/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene IL33","url":"https://civicdb.org/features/16802","note":"1 evidence items, 0 assertions, 1 variants; diseases: High Grade Glioma (GraphQL API, CC0)"}],"hgnc":"HGNC:16028","ensembl":"ENSG00000137033","uniprot":"O95760","entrez":"90865","biology":"Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signalling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as an enhancer of polarisation of alternatively activated macrophages. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury. Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages. Location: Nucleus; Chromosome; Cytoplasm; Cytoplasmic vesicle, secretory vesicle (UniProt). Locus 9p24.1 (HGNC).","whereFound":[],"targetClass":"transcription","prevalence":[]},"route":"/targets/il33/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}]}}